Advertisement
Home »

EV/Pembrolizumab Raises the Bar for OS in Metastatic Urothelial Cancer

Oct 27, 2023

REFERENCES & ADDITIONAL READING

Powles TB, et al. Lancet Oncol 2021;22(7):931–945.

 

Galsky MD, et al. Lancet 2020;395(10236):1547–1557.

 

Powles TB, et al. N Engl J Med. 2021;384:1125–1135.

 

Powles TB, et al. EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Abstract LBA6, ESMO 2023, 20–24 October, Madrid, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement